
Health Check 2025: A big year for tackling malaria
Dec 24, 2025
In this insightful discussion, James Tibenderana, Chief Executive at the Malaria Consortium, shares vital advancements in malaria control for 2025, including breakthroughs in vaccine rollout and new treatment strategies. Abdoulaye Djimdé, Professor of Parasitology, details the clinical success of a new drug, Ganaplacide-lumefantrine, and its unique mechanism against resistance. Ellie Sherrard-Smith explains the innovative passive spatial emanators designed for indoor mosquito control, highlighting their role in reducing malaria transmission. The stakes are high amid funding cuts affecting global health initiatives.
AI Snips
Chapters
Transcript
Episode notes
A Breakthrough Year For Malaria
- 2025 delivered multiple, complementary breakthroughs across treatment, prevention and formulations.
- These advances together renewed practical hope for accelerating malaria control and elimination.
Clinic Pressure And Self-Treatment In Nigeria
- Dr Onyinye Echedike-Elekwa described heavy caseloads with malaria as the most common illness seen in children and adults.
- Patients often self-treat with over-the-counter artemisinin combos, delaying clinic care and complicating diagnosis.
Partial Drug Resistance Poses Big Risk
- Partial artemisinin resistance means slower parasite clearance rather than complete treatment failure.
- This partial resistance risks eroding two decades of progress if alternative drugs aren't scaled up.


